{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["McCoach CE"],"funding":["University of Colorado Lung Cancer SPORE","NCI NIH HHS"],"pagination":["2758-2770"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6157019"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(12)"],"pubmed_abstract":["<b>Purpose:</b> Patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor anaplastic lymphoma kinase (<i>ALK)</i> gene fusions benefit from treatment with ALK inhibitors (ALKi). Analysis of cell-free circulating tumor DNA (cfDNA) may provide a noninvasive way to identify <i>ALK</i> fusions and actionable resistance mechanisms without an invasive biopsy.<b>Patients and Methods:</b> The Guardant360 (G360; Guardant Health) deidentified database of NSCLC cases was queried to identify 88 consecutive patients with 96 plasma-detected <i>ALK</i> fusions. G360 is a clinical cfDNA next-generation sequencing (NGS) test that detects point mutations, select copy number gains, fusions, insertions, and deletions in plasma.<b>Results:</b> Identified fusion partners included <i>EML4</i>"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Clinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer."],"pmcid":["PMC6157019"],"funding_grant_id":["P50 CA058187","P30 CA046934","P50CA058187","R01 CA193935"],"pubmed_authors":["Waqar SN","Shaw AT","McCoach CE","Le AT","Levy B","Purcell WT","Chue BM","Blakely CM","Davies KD","Lanman RB","Banks KC","Diaz J","Aisner DL","Raymond VM","Doebele RC","Lee CE"],"additional_accession":[]},"is_claimable":false,"name":"Clinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.","description":"<b>Purpose:</b> Patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor anaplastic lymphoma kinase (<i>ALK)</i> gene fusions benefit from treatment with ALK inhibitors (ALKi). Analysis of cell-free circulating tumor DNA (cfDNA) may provide a noninvasive way to identify <i>ALK</i> fusions and actionable resistance mechanisms without an invasive biopsy.<b>Patients and Methods:</b> The Guardant360 (G360; Guardant Health) deidentified database of NSCLC cases was queried to identify 88 consecutive patients with 96 plasma-detected <i>ALK</i> fusions. G360 is a clinical cfDNA next-generation sequencing (NGS) test that detects point mutations, select copy number gains, fusions, insertions, and deletions in plasma.<b>Results:</b> Identified fusion partners included <i>EML4</i>","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jun","modification":"2025-04-04T11:20:49.222Z","creation":"2019-03-27T00:11:25Z"},"accession":"S-EPMC6157019","cross_references":{"pubmed":["29599410"],"doi":["10.1158/1078-0432.CCR-17-2588","10.1158/1078-0432.ccr-17-2588"]}}